Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium
Ana Babić(Harvard University), Kathryn L. Terry(Brigham and Women's Hospital), Helen Steed(University of Alberta), Penelope M. Webb(QIMR Berghofer Medical Research Institute), Melissa Moffitt(Oregon Health & Science University), Sharon E. Johnatty(QIMR Berghofer Medical Research Institute), Claus Høgdall(Copenhagen University Hospital), Florian Heitz(Kliniken Essen-Mitte), Linda E. Kelemen(Medical University of South Carolina), Anna DeFazio(The University of Sydney), Estrid Høgdall(University of Copenhagen), Allan Jensen(Danish Cancer Society), Marc T. Goodman(Cedars-Sinai Medical Center), Daniel W. Cramer(Brigham and Women's Hospital), Keitaro Matsuo(Aichi Cancer Center), Tanja Pejović(Oregon Health & Science University), Diether Lambrechts(VIB-KU Leuven Center for Cancer Biology), Satoyo Hosono(Aichi Cancer Center), Beth Y. Karlan(University of California, Los Angeles), Martin Köbel(University of Calgary), Iain A. McNeish(Imperial College London), Susanne K. Kjær(Copenhagen University Hospital), Ellen L. Goode(Mayo Clinic in Arizona)
Cited by 41
Related Papers
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
|Clinical Cancer Research|2008|1.5k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k